All In Biotech

Free tool

FAERS Monitor: Sodium Iodide I 123

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018671 or its brand name (Sodium Iodide I 123, Sodium Iodide I-123). Reports on generic versions are filed under their own applications.

Reports

940

Serious

896

95% of reports

Hospitalization

63

Death reported

45

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypothyroidism384
  • endocrine ophthalmopathy36
  • treatment failure26
  • acute myeloid leukaemia24
  • dacryostenosis acquired24
  • parathyroid tumour benign21
  • abortion spontaneous20
  • hyperthyroidism20
  • hyperparathyroidism19
  • lacrimation increased19
  • breast cancer17
  • maternal exposure during pregnancy17
  • thyroid cancer17
  • nausea16
  • sialoadenitis16

Reports by year received

View as table
YearReports
20051
20061
200733
200876
200956
201056
2011263
2012173
201382
201414
201517
201613
20175
201826
201948
202013
202148
20228
20243
20251
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,219 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
endocrine ophthalmopathySignal36969.1698.532,452
parathyroid tumour benignSignal21652.3424.712,646
dacryostenosis acquiredSignal24423.9284.59,528
hypothyroidismSignal384272.4252.0102,458
sialoadenitisSignal16265.8163.13,915
hyperparathyroidismSignal19208.2133.13,679
acute myeloid leukaemiaSignal2434.523.2747
thyroid cancerSignal1731.719.8474
hyperthyroidismSignal2031.020.1550
lacrimation increasedSignal1914.19.0218
abortion spontaneousSignal2011.27.2175
treatment failureSignal267.04.8129
maternal exposure during pregnancySignal174.32.740
breast cancerSignal174.12.537
nausea160.50.310

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.